Drug intelligence / Profile preview

RJ027

Development stage: Preclinical
Lead developer: Runjia
Modality: Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics

Overview

RJ027 is a preclinical-stage small interfering RNA (siRNA) therapeutic being developed by Risen Pharma for the treatment of Alzheimer's disease. Utilizing RNA interference (RNAi) technology, RJ027 is designed to specifically target and degrade messenger RNA (mRNA) transcripts associated with the progression of Alzheimer's, thereby inhibiting the synthesis of disease-driving proteins. As of 2024, the program remains in the preclinical phase of development.

Beyond the preview

Go deeper on RJ027.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RJ027.

Explore the full profile